Certainly the chance for the oppies was severely diminished by the ANN that the trial results report would not be available in the current quarter but delayed until Jan 2013.
Putting the cynical hat on, one could ask if this was a very cynical move to ensure that the SHs c500M oppies would expire and hence not dilute the number of shares on issue? After the report is issued in Jan proving what a fantastic product ArTiMist is the share price could soar and hence ensuring that the other oppies on offer were well and truly in the money with the advantage of the non dilution of the share pool. It would also, after a successful report, and the conversion of the oppies , be very easy to go back to the market and raise some more money.
But only a cynic would take that view and not long term EMS shareholders.
kippax
EMS Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
